Precision Oncology in 2026: Five Trials Redefining What Cancer Treatment Can Be
Introduction
Precision oncology is no longer a future aspiration — it is an increasingly specific set of tools and clinical evidence being generated in real time. 2026 has delivered a cluster of research milestones across molecular targeting, gene editing, and next-generation immunotherapy that collectively suggest oncology is entering a period of genuinely accelerated progress.
Gedatolisib Delivers for a Resistant Breast Cancer Subgroup
New data from the VIKTORIA-1 study evaluating gedatolisib in hormone receptor-positive, HER2-negative advanced breast cancer — specifically in PIK3CA wild-type patients — is among the most clinically significant recent releases. Existing PI3K alpha-selective inhibitors are ineffective in wild-type patients. Gedatolisib, a pan-PI3K/mTOR inhibitor, demonstrated strong progression-free survival improvements in exactly this underserved subgroup. The therapy has received FDA Priority Review, with a regulatory decision expected in 2026.
Dewpoint Breaks Ground in Condensate Biology for Solid Tumors
Dewpoint Therapeutics launched a solid tumor study exploring its condensate biology platform — an approach that disrupts the dynamic molecular condensates through which oncoproteins exert their effects. This is conceptually distinct from conventional targeted therapies. If early clinical data validate the mechanism, it would represent a genuinely new category of cancer drug.
CRISPR Engineering Enters Solid Tumor Immunotherapy
T-knife Therapeutics received authorization to begin a Phase 1 trial of TK-6302, a CRISPR-engineered T-cell therapy targeting PRAME — an antigen expressed across melanoma, lung, and ovarian cancer. CRISPR editing removes endogenous T-cell receptor genes and inserts a high-affinity tumor-targeting receptor, creating a precision immune product. TK-6302 also incorporates features to counter the immunosuppressive tumor microenvironment that has historically defeated cell therapies in solid tumors.
Ascentage Pharma’s AACR Data Highlights Resistance Targeting
At AACR Annual Meeting 2026, Ascentage Pharma presented preclinical combination strategies across olverembatinib, APG-2449, and APG-5918 — demonstrating synergy in models of mantle cell lymphoma, endometrial carcinoma, BRAF-mutant tumors, and small-cell lung cancer. Identifying combinations that delay resistance without prohibitive toxicity is one of the central problems in modern precision medicine, and Ascentage’s AACR presence reflects serious investment in answering it.
Neomorph Initiates First Human Dosing with NEO-811
Neomorph dosed its first cancer trial patient in the NEO-811 study, advancing a targeted protein degradation compound into human evaluation. Degraders use the cell’s own machinery to eliminate disease-causing proteins entirely — including those without conventional druggable binding sites. This expands the oncology target universe in ways that traditional small molecules simply cannot.
Stay current on emerging oncology data and trial launches at clinical trial vanguard for ongoing oncology trial coverage
Conclusion
Gedatolisib filling a breast cancer gap, CRISPR engineering immune cells for solid tumors, Dewpoint’s novel mechanism, Ascentage’s resistance strategies, and Neomorph’s protein degrader program — these five developments reflect a precision oncology field pursuing multiple converging paths simultaneously. The speed and breadth of this progress is genuinely unprecedented.
